322 related articles for article (PubMed ID: 33770101)
1. Short-term treatment of golden retriever muscular dystrophy (GRMD) dogs with rAAVrh74.MHCK7.GALGT2 induces muscle glycosylation and utrophin expression but has no significant effect on muscle strength.
Martin PT; Zygmunt DA; Ashbrook A; Hamilton S; Packer D; Birch SM; Bettis AK; Balog-Alvarez CJ; Guo LJ; Nghiem PP; Kornegay JN
PLoS One; 2021; 16(3):e0248721. PubMed ID: 33770101
[TBL] [Abstract][Full Text] [Related]
2. Vascular delivery of rAAVrh74.MCK.GALGT2 to the gastrocnemius muscle of the rhesus macaque stimulates the expression of dystrophin and laminin α2 surrogates.
Chicoine LG; Rodino-Klapac LR; Shao G; Xu R; Bremer WG; Camboni M; Golden B; Montgomery CL; Shontz K; Heller KN; Griffin DA; Lewis S; Coley BD; Walker CM; Clark KR; Sahenk Z; Mendell JR; Martin PT
Mol Ther; 2014 Apr; 22(4):713-24. PubMed ID: 24145553
[TBL] [Abstract][Full Text] [Related]
3. rAAVrh74.MCK.GALGT2 Protects against Loss of Hemodynamic Function in the Aging mdx Mouse Heart.
Xu R; Jia Y; Zygmunt DA; Martin PT
Mol Ther; 2019 Mar; 27(3):636-649. PubMed ID: 30711447
[TBL] [Abstract][Full Text] [Related]
4. Non-immunogenic utrophin gene therapy for the treatment of muscular dystrophy animal models.
Song Y; Morales L; Malik AS; Mead AF; Greer CD; Mitchell MA; Petrov MT; Su LT; Choi ME; Rosenblum ST; Lu X; VanBelzen DJ; Krishnankutty RK; Balzer FJ; Loro E; French R; Propert KJ; Zhou S; Kozyak BW; Nghiem PP; Khurana TS; Kornegay JN; Stedman HH
Nat Med; 2019 Oct; 25(10):1505-1511. PubMed ID: 31591596
[TBL] [Abstract][Full Text] [Related]
5. B4GALNT2 (GALGT2) Gene Therapy Reduces Skeletal Muscle Pathology in the FKRP P448L Mouse Model of Limb Girdle Muscular Dystrophy 2I.
Thomas PJ; Xu R; Martin PT
Am J Pathol; 2016 Sep; 186(9):2429-48. PubMed ID: 27561302
[TBL] [Abstract][Full Text] [Related]
6. Dose-Escalation Study of Systemically Delivered rAAVrh74.MHCK7.micro-dystrophin in the
Potter RA; Griffin DA; Heller KN; Peterson EL; Clark EK; Mendell JR; Rodino-Klapac LR
Hum Gene Ther; 2021 Apr; 32(7-8):375-389. PubMed ID: 33397205
[TBL] [Abstract][Full Text] [Related]
7. Assessment of Systemic Delivery of rAAVrh74.MHCK7.micro-dystrophin in Children With Duchenne Muscular Dystrophy: A Nonrandomized Controlled Trial.
Mendell JR; Sahenk Z; Lehman K; Nease C; Lowes LP; Miller NF; Iammarino MA; Alfano LN; Nicholl A; Al-Zaidy S; Lewis S; Church K; Shell R; Cripe LH; Potter RA; Griffin DA; Pozsgai E; Dugar A; Hogan M; Rodino-Klapac LR
JAMA Neurol; 2020 Sep; 77(9):1122-1131. PubMed ID: 32539076
[TBL] [Abstract][Full Text] [Related]
8. Deletion of Galgt2 (B4Galnt2) reduces muscle growth in response to acute injury and increases muscle inflammation and pathology in dystrophin-deficient mice.
Xu R; Singhal N; Serinagaoglu Y; Chandrasekharan K; Joshi M; Bauer JA; Janssen PM; Martin PT
Am J Pathol; 2015 Oct; 185(10):2668-84. PubMed ID: 26435413
[TBL] [Abstract][Full Text] [Related]
9. rAAVrh74.MCK.
Zygmunt DA; Xu R; Jia Y; Ashbrook A; Menke C; Shao G; Yoon JH; Hamilton S; Pisharath H; Bolon B; Martin PT
Mol Ther Methods Clin Dev; 2019 Dec; 15():305-319. PubMed ID: 31890730
[TBL] [Abstract][Full Text] [Related]
10. Dystrophic phenotype of canine X-linked muscular dystrophy is mitigated by adenovirus-mediated utrophin gene transfer.
Cerletti M; Negri T; Cozzi F; Colpo R; Andreetta F; Croci D; Davies KE; Cornelio F; Pozza O; Karpati G; Gilbert R; Mora M
Gene Ther; 2003 May; 10(9):750-7. PubMed ID: 12704413
[TBL] [Abstract][Full Text] [Related]
11. Sarcospan increases laminin-binding capacity of α-dystroglycan to ameliorate DMD independent of Galgt2.
Mamsa H; Stark RL; Shin KM; Beedle AM; Crosbie RH
Hum Mol Genet; 2022 Mar; 31(5):718-732. PubMed ID: 34581784
[TBL] [Abstract][Full Text] [Related]
12. Assessment of systemic AAV-microdystrophin gene therapy in the GRMD model of Duchenne muscular dystrophy.
Birch SM; Lawlor MW; Conlon TJ; Guo LJ; Crudele JM; Hawkins EC; Nghiem PP; Ahn M; Meng H; Beatka MJ; Fickau BA; Prieto JC; Styner MA; Struharik MJ; Shanks C; Brown KJ; Golebiowski D; Bettis AK; Balog-Alvarez CJ; Clement N; Coleman KE; Corti M; Pan X; Hauschka SD; Gonzalez JP; Morris CA; Schneider JS; Duan D; Chamberlain JS; Byrne BJ; Kornegay JN
Sci Transl Med; 2023 Jan; 15(677):eabo1815. PubMed ID: 36599002
[TBL] [Abstract][Full Text] [Related]
13. Muscle function recovery in golden retriever muscular dystrophy after AAV1-U7 exon skipping.
Vulin A; Barthélémy I; Goyenvalle A; Thibaud JL; Beley C; Griffith G; Benchaouir R; le Hir M; Unterfinger Y; Lorain S; Dreyfus P; Voit T; Carlier P; Blot S; Garcia L
Mol Ther; 2012 Nov; 20(11):2120-33. PubMed ID: 22968479
[TBL] [Abstract][Full Text] [Related]
14. The golden retriever model of Duchenne muscular dystrophy.
Kornegay JN
Skelet Muscle; 2017 May; 7(1):9. PubMed ID: 28526070
[TBL] [Abstract][Full Text] [Related]
15. The value of mammalian models for duchenne muscular dystrophy in developing therapeutic strategies.
Banks GB; Chamberlain JS
Curr Top Dev Biol; 2008; 84():431-53. PubMed ID: 19186250
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of the cytotoxic T cell (CT) carbohydrate inhibits muscular dystrophy in the dyW mouse model of congenital muscular dystrophy 1A.
Xu R; Chandrasekharan K; Yoon JH; Camboni M; Martin PT
Am J Pathol; 2007 Jul; 171(1):181-99. PubMed ID: 17591965
[TBL] [Abstract][Full Text] [Related]
17. The synaptic CT carbohydrate modulates binding and expression of extracellular matrix proteins in skeletal muscle: Partial dependence on utrophin.
Yoon JH; Chandrasekharan K; Xu R; Glass M; Singhal N; Martin PT
Mol Cell Neurosci; 2009 Aug; 41(4):448-63. PubMed ID: 19442736
[TBL] [Abstract][Full Text] [Related]
18. Repression of phosphatidylinositol transfer protein α ameliorates the pathology of Duchenne muscular dystrophy.
Vieira NM; Spinazzola JM; Alexander MS; Moreira YB; Kawahara G; Gibbs DE; Mead LC; Verjovski-Almeida S; Zatz M; Kunkel LM
Proc Natl Acad Sci U S A; 2017 Jun; 114(23):6080-6085. PubMed ID: 28533404
[TBL] [Abstract][Full Text] [Related]
19. Glucose Metabolism as a Pre-clinical Biomarker for the Golden Retriever Model of Duchenne Muscular Dystrophy.
Schneider SM; Sridhar V; Bettis AK; Heath-Barnett H; Balog-Alvarez CJ; Guo LJ; Johnson R; Jaques S; Vitha S; Glowcwski AC; Kornegay JN; Nghiem PP
Mol Imaging Biol; 2018 Oct; 20(5):780-788. PubMed ID: 29508262
[TBL] [Abstract][Full Text] [Related]
20. Canine models of Duchenne muscular dystrophy and their use in therapeutic strategies.
Kornegay JN; Bogan JR; Bogan DJ; Childers MK; Li J; Nghiem P; Detwiler DA; Larsen CA; Grange RW; Bhavaraju-Sanka RK; Tou S; Keene BP; Howard JF; Wang J; Fan Z; Schatzberg SJ; Styner MA; Flanigan KM; Xiao X; Hoffman EP
Mamm Genome; 2012 Feb; 23(1-2):85-108. PubMed ID: 22218699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
